DBVT Stock Summary and Trading Ideas (DBV Technologies S.A. - American Depositary Shares | NASDAQ:DBVT)

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Viaskin targets specific antigen-presenting immune cells in the skin, called Langerhans cells, that capture the antigen and migrate to the lymph node to activate the immune system without passage of the antigen into the bloodstream, minimizing systemic exposure in the body. Its main product candidate is Viaskin Peanut for the treatment of peanut-allergic patients.

DBV Technologies S.A. - American Depositary Shares trades on the NASDAQ stock market under the symbol DBVT.

As of January 17, 2025, DBVT stock price declined to $4.47 with 26,892 million shares trading.

DBVT has a market cap of $91.61 million. This is considered a Micro Cap stock.

Last quarter DBV Technologies S.A. - American Depositary Shares reported $1 million in Revenue and -$1.60 earnings per share. This fell short of revenue expectation by $-308,000 and exceeded earnings estimates by $.15.

In the last 3 years, DBVT traded as high as $34.30 and as low as $2.20.

DBVT has underperformed the market in the last year with a return of -48.1%, while SPY returned +28.0%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in DBVT shares. However, DBVT has outperformed the market in the last 3 month and 2 week periods, returning +24.0% and +32.9%, while SPY returned +3.0% and +1.0%, respectively. This indicates DBVT has been having a stronger performance recently.

DBVT support price is $4.36 and resistance is $5.10 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that DBVT shares will trade within this expected range on the day.